SOLACI-SOCIME 2022 – LIVE CASE 2 | Pulmonary Valve Implantation with a Melody Prosthesis

✔️ Live Case 2, Main Arena – SOLACI-SOCIME 2022

✔️ SOLACI-SOCIME 2022 Video


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

LIVE CASE “VitaFlow” FROM “SANATORIO FINOCHIETTO” BA, ARGENTINA – SOLACI-SOCIME 2022

✔️ LIVE CASE “VitaFlow” FROM “SANATORIO FINOCHIETTO” BA, ARGENTINA - SOLACI-SOCIME 2022 ✔️ Video del SOLACI-SOCIME 2022

LIVE CASE “Pulmonar Valve” from Hospital Universitario Austral, BA, Argentina – SOLACI-SOCIME 2022

✔️ LIVE CASE “Pulmonar Valve” from “Hospital Universitario Austral, BA, Argentina - SOLACI-SOCIME 2022. Structural Room. ✔️ SOLACI-SOCIME 2022 Scientific Session.

SOLACI-SOCIME 2022: Live Cases from Centro Médico Nacional Siglo XXI, Mexico City

✔️ SOLACI-SOCIME 2022: Live Cases from Centro Médico Nacional Siglo XXI, Mexico City. ✔️ SOLACI-SOCIME 2022 Scientific Session. 

SOLACI-SOCIME 2022 – Live Cases from Centro Médico Nacional: 20 de Noviembre, Mexico City

✔️ SOLACI-SOCIME 2022 - Live Cases from Centro Médico Nacional: 20 de Noviembre, Mexico City ✔️ SOLACI-SOCIME 2022 Scientific Session

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....